本文關(guān)鍵詞： 乳腺癌 時(shí)辰化療 腋窩淋巴結(jié)轉(zhuǎn)移灶 臨床療效　出處：《廣州中醫(yī)藥大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：對比分析以子午流注理論指導(dǎo)下建立的丑時(shí)TEC新輔助化療方案與常規(guī)TEC方案在局部晚期乳腺癌治療中的療效及不良反應(yīng),擬證實(shí)丑時(shí)行TEC化療治療乳腺癌的優(yōu)越性,并證實(shí)子午流注理論指導(dǎo)乳腺癌化療的科學(xué)性與可行性。方法：分析我院2013年3月至2014年12月乳腺科收治的53例確診乳腺癌患者,依據(jù)術(shù)前化療方案不同進(jìn)行臨床分組,TEC丑時(shí)化療組(治療組)21例和TEC日間常規(guī)化療組(對照組)32例。行3周期的新輔助化療后,比較兩組原發(fā)腫瘤、腋窩淋巴結(jié)新輔助化療的療效變化及不良反應(yīng)發(fā)生情況。結(jié)果：治療組、對照組有效率(RR=CR+PR)、病理完全緩解率(pCR)、臨床完全緩解率(cCR)、部分緩解率(PR)、維持穩(wěn)定(SD)分別為76.2%、14.3%、19%、57.1%、23.8%與59.4%、6.25%、9.4%、50%、40.6%,兩組有效率相比具有統(tǒng)計(jì)學(xué)意義(P0.05)。分層分析中,兩組原發(fā)腫瘤有效率分別為66.7%、56.25%,差異沒有統(tǒng)計(jì)學(xué)意義(P0.05)；治療組腋窩淋巴結(jié)轉(zhuǎn)移灶有效率優(yōu)于對照組(66.7% vs 53.1%)(P0.05)；乳房原發(fā)腫瘤有效率與腋窩淋巴結(jié)轉(zhuǎn)移灶有效率相當(dāng)(62.7% vs 58.5%),無統(tǒng)計(jì)學(xué)差異(P0.05)。化療過程中兩組白細(xì)胞減少發(fā)生率相當(dāng)(66.7% vs 68.9%),無統(tǒng)計(jì)學(xué)差異(P0.05),治療組的惡心嘔吐及周圍神經(jīng)異常發(fā)生率低于對照組,具有統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論：本研究提示丑時(shí)行TEC新輔助化療治療局部晚期乳腺癌的療效高于常規(guī)TEC化療,并且毒副反應(yīng)小,安全可靠,臨床可以運(yùn)用。
[Abstract]:Objective: to compare and analyze the curative effect and adverse reactions of TEC neo-adjuvant chemotherapy regimen and routine TEC regimen in the treatment of locally advanced breast cancer under the guidance of Meridian abortion theory, in order to prove the superiority of TEC chemotherapy in the treatment of breast cancer. Methods: 53 patients with breast cancer admitted from March 2013 to December 2014 in our hospital were analyzed. According to the different preoperative chemotherapy regimen, the patients were divided into two groups: the treatment group (21 cases) and the control group (32 cases). After 3 cycles of neoadjuvant chemotherapy, the primary tumors were compared between the two groups. Effect of neoadjuvant chemotherapy on axillary lymph nodes and adverse reactions. Results: treatment group, In the control group, the effective rates of RRN CR PRA, pathological complete remission rate, clinical complete remission rate and partial remission rate were 76.2%, 14.31% and 57.18%, respectively, compared with 59.4% 6.4505040.640.60.The effective rates of the two groups were significantly higher than that of the control group (P 0.05). In the stratified analysis, the effective rate of the two groups was significantly higher than that of the control group (P < 0.05). The effective rate of primary tumor in the two groups was 66.7% and 56.25, respectively. There was no significant difference between the two groups (P 0.05); the effective rate of axillary lymph node metastasis in the treatment group was better than that in the control group (66.7% vs 53.1%; the effective rate of primary breast tumor was 62.7% vs the effective rate of axillary lymph node metastasis was 62.7%). The incidence of leukopenia in the two groups was 66.7% vs 68.9%, and there was no statistical difference between the two groups (P 0.05). The incidence of nausea and vomiting and peripheral nerve abnormality in the treatment group was lower than that in the control group. Conclusion: this study suggests that TEC neoadjuvant chemotherapy is more effective than conventional TEC chemotherapy in the treatment of locally advanced breast cancer, and its toxicity is small, safe and reliable, and can be used clinically.
【學(xué)位授予單位】：廣州中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R737.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王殊;張嘉慶;喬新民;楊德啟;佟富中;;新輔助化療后乳腺癌病理變化31例分析[J];中國婦產(chǎn)科臨床雜志;2007年04期

2 韋艷碧;中醫(yī)擇時(shí)服藥治療胃脘痛104例[J];廣西中醫(yī)藥;2003年02期

3 寧全福;李航森;;從肝郁論治乳腺癌體會(huì)[J];河北中醫(yī);2007年10期

4 馮龍;李凌;郭武華;吳建兵;;介入治療聯(lián)合時(shí)辰化療治療晚期胃癌的臨床觀察[J];實(shí)用臨床醫(yī)學(xué);2008年08期

5 鐘麗;吳敬波;;腫瘤時(shí)辰治療的臨床研究進(jìn)展[J];實(shí)用癌癥雜志;2008年03期

6 張潔文;;子午流注法穴位貼敷治療化療所致嘔吐的療效觀察[J];實(shí)用心腦肺血管病雜志;2013年09期

7 郭鵬;王正榮;;腫瘤生物節(jié)律治療[J];腫瘤預(yù)防與治療;2010年06期

8 蔡仁英;子午流注學(xué)說與肺心病擇時(shí)服藥護(hù)理探討[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2000年05期

9 陳昕;梁超;雷開鍵;賈鈺銘;杜一平;;時(shí)辰化療作用機(jī)制的生物學(xué)研究進(jìn)展[J];現(xiàn)代預(yù)防醫(yī)學(xué);2008年02期

10 粟世勇;化療方案時(shí)辰給藥方法治療晚期乳腺癌的臨床觀察[J];右江醫(yī)學(xué);2004年06期

，

本文編號(hào)：1527134